Abcellera Biologics Inc
ABCL3.160USD
+0.380+13.67%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
944.88MMarket Cap
LossP/E TTM
More Details of Abcellera Biologics Inc Company
AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs.
Abcellera Biologics Inc Info
Ticker SymbolABCL
Company nameAbcellera Biologics Inc
IPO dateDec 11, 2020
CEOHansen (Carl L.G)
Number of employees596
Security typeOrdinary Share
Fiscal year-endDec 11
Address150 W 4Th Avenue
CityVANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV5Y 1G6
Phone16045599005
Websitehttps://www.abcellera.com/
Ticker SymbolABCL
IPO dateDec 11, 2020
CEOHansen (Carl L.G)
Company Executives of Abcellera Biologics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Dr. Sarah B. Noonberg, M.D., Ph.D.
Dr. Sarah B. Noonberg, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Stephen Quake
Mr. Stephen Quake
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Veronique Lecault, Ph.D.
Dr. Veronique Lecault, Ph.D.
Co-Founder, Chief Operating Officer, Director
Co-Founder, Chief Operating Officer, Director
9.61M
--
Mr. Andrew Booth
Mr. Andrew Booth
Chief Financial Officer
Chief Financial Officer
283.96K
--
Dr. Carl L.G. Hansen, Ph.D.
Dr. Carl L.G. Hansen, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
--
--
Mr. Tryn T. Stimart, J.D.
Mr. Tryn T. Stimart, J.D.
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary and Privacy Officer
--
--
Dr. Michael R. Hayden
Dr. Michael R. Hayden
Lead Independent Director
Lead Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2024Q2
FY2023Q2
By BusinessUSD
Name
Revenue
Proportion
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Research fees
8.82M
98.46%
Licensing revenue
138.00K
1.54%
Shareholding Stats
Updated: Sun, Jan 25
Updated: Sun, Jan 25
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Other
61.11%
Shareholders
Shareholders
Proportion
Thermopylae Holdings Ltd
18.68%
Baker Bros. Advisors LP
9.20%
Capital World Investors
4.46%
Two Sigma Investments, LP
3.34%
Lecault (Veronique)
3.21%
Other
61.11%
Shareholder Types
Shareholders
Proportion
Corporation
18.68%
Hedge Fund
16.25%
Investment Advisor
9.45%
Individual Investor
4.29%
Investment Advisor/Hedge Fund
3.93%
Research Firm
2.06%
Bank and Trust
0.69%
Pension Fund
0.29%
Sovereign Wealth Fund
0.21%
Other
44.14%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
315
112.27M
50.73%
-101.09K
2025Q3
340
112.51M
51.75%
-3.28M
2025Q2
368
115.12M
53.94%
-18.45M
2025Q1
420
133.63M
52.62%
-23.37M
2024Q4
441
121.95M
50.14%
+4.83M
2024Q3
440
121.95M
51.59%
-4.54M
2024Q2
439
127.07M
51.27%
-6.55M
2024Q1
432
134.44M
53.43%
-22.43M
2023Q4
425
138.44M
60.93%
-1.40M
2023Q3
426
134.18M
60.12%
-4.59M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Thermopylae Holdings Ltd
55.92M
18.68%
-225.00K
-0.40%
Dec 18, 2025
Baker Bros. Advisors LP
27.53M
9.2%
--
--
Sep 30, 2025
Capital World Investors
13.36M
4.46%
--
--
Sep 30, 2025
Two Sigma Investments, LP
9.99M
3.34%
+1.81M
+22.09%
Sep 30, 2025
Lecault (Veronique)
9.61M
3.21%
--
--
Apr 01, 2025
ArrowMark Colorado Holdings, LLC
4.11M
1.37%
--
--
Sep 30, 2025
Renaissance Technologies LLC
3.36M
1.12%
+53.30K
+1.61%
Sep 30, 2025
Tang Capital Management, LLC
2.60M
0.87%
--
--
Sep 30, 2025
Morgan Stanley & Co. LLC
2.56M
0.85%
+1.79M
+234.13%
Sep 30, 2025
Millennium Management LLC
2.43M
0.81%
-967.85K
-28.49%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
2.64%
Virtus LifeSci Biotech Clinical Trials ETF
1.19%
ProShares Ultra Nasdaq Biotechnology
0.16%
Invesco Nasdaq Biotechnology ETF
0.16%
SPDR S&P International Small Cap ETF
0.12%
iShares Biotechnology ETF
0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
0.05%
Avantis US Small Cap Equity ETF
0.01%
SPDR Portfolio Developed World ex-US ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion2.64%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.16%
Invesco Nasdaq Biotechnology ETF
Proportion0.16%
SPDR S&P International Small Cap ETF
Proportion0.12%
iShares Biotechnology ETF
Proportion0.11%
Invesco RAFI Developed Mkts ex-US SM ETF
Proportion0.05%
Avantis US Small Cap Equity ETF
Proportion0.01%
SPDR Portfolio Developed World ex-US ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
